Clinical evaluation of ambenonium (mysuran) chloride
| Autor: | Martha R. Westerberg |
|---|---|
| Rok vydání: | 1956 |
| Předmět: |
Ions
business.industry medicine.disease Chloride Acetylcholinesterase Myasthenia gravis Acute toxicity Neostigmine Ambenonium Chloride Ambenonium chemistry.chemical_compound Atropine Arts and Humanities (miscellaneous) chemistry Chlorides Parasympathomimetics Anesthesia Myasthenia Gravis medicine Ambenonium chloride Neurology (clinical) business medicine.drug |
| Zdroj: | A.M.A. archives of neurology and psychiatry. 75(1) |
| ISSN: | 0096-6886 |
| Popis: | This report is concerned with the results of the use of ambenonium in patients with myasthenia gravis during the past year. Ambenonium (Mysuran) chloride is N'N'-bis (2-diethylaminoethyl) oxamide bis-2-chlorobenzyl chloride, or C28H42C14N402. Its formula is Pharmacologic investigation by Winthrop-Stearns, Inc., has shown that ambenonium chloride has anticholinesterase properties, which are specific against acetylcholinesterase, with only weak activity against serum cholinesterase, and that its activity is from 5 to 13 times that of neostigmine. In animal experiments, ambenonium was two to four times as active in antagonizing tubocurarine paralysis, and the effect was of much longer duration. The curarizing effect of ambenonium occurred only with doses approximately 1000 times the therapeutic level. Its acute toxicity in animals was one-tenth that of neostigmine, and its side-effects were characteristic of parasympathetic stimulation and were controlled by atropine. The present study concerns the evaluation of the effect of ambenonium chloride in patients with myasthenia |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|